Literature DB >> 12865563

A study of anti-neutrophil cytoplasm antibodies in systemic vasculitis and other related disorders.

V D Pradhan1, S S Badakere, Y S Iyer, R Kumar, A F Almeida.   

Abstract

BACKGROUND: Anti-neutrophil cytoplasm antibodies (ANCA) play an important role as specific and sensitive markers for small vessel vasculitis and in some other systemic disorders. Indirect immunofluorescence test, known as the "Gold Standard" for screening of ANCA, can be further substantiated by ELISA for confirmation and for identifying sub-specificities like anti-Myeloperoxidase (anti-MPO), anti-Proteinase 3 (anti-PR3) and anti-Lactoferrin (anti-LF). AIMS: The present study was undertaken to investigate the incidence, specificities and strength of ANCA in suspected vasculitis cases and to correlate their presence with that of these auto-antibodies and with the disease. SUBJECTS AND METHODS: Sera from 130 clinically suspected vasculitis patients were studied. Indirect immunofluorescence microscopy (IIF) was used to identify cytoplasmic (c-ANCA), perinuclear (p-ANCA) and atypical (X-ANCA) patterns using ethanol and formalin fixed polymorphonuclear cells (PMN) and HL-60 cells from a human promyelocytic leukaemic cell line as substrates. ELISA was performed for identifying ANCA sub-specificities to anti-MPO and anti-PR3 and HEp-2 cells were used for detection of anti-nuclear antibodies (ANA).
RESULTS: ANCA positivity was noted in 42.3% of these patients, wherein p-ANCA positivity rate was 34.6% and c-ANCA positivity was noted in 5.4% subjects. Three patients showed the unusual X-ANCA positivity. ELISA determined the sub-specificities: Out of 45 p-ANCA positive patients, 38 patients (84.4%) had anti-MPO and out of 7 c-ANCA positive patients, 5 patients (71.4%) had anti-PR3 antibodies. One patient with Class IV Lupus Nephritis, showed both anti-MPO and anti-PR3 antibodies and 17.8% p-ANCA positive patients had anti-Lactoferrin antibodies.
CONCLUSIONS: Use of the Immunofluorescence method coupled with identification of ANCA sub-specificities by ELISA, is recommended for detection of ANCA in clinically suspected cases of small vessel and other systemic vasculitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865563     DOI: 10.4103/0022-3859.936

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  6 in total

1.  Use of immunofluorescence and confocal laser scanning microscopy in identifying rare cases of anti-neutrophil cytoplasmic antibodies (ANCA) showing dual specificities to myeloperoxidase and proteinase3.

Authors:  S S Badakere; Vandana D Pradhan; A F Almeida; Aruna R Pawar
Journal:  J Fluoresc       Date:  2004-07       Impact factor: 2.217

2.  Anti-idiotype antibodies in immune regulation of anca associated vasculitis.

Authors:  Vandana D Pradhan; Kanjaksha Ghosh
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

3.  Background noise of infection for using ANCA as a diagnostic tool for vasculitis in tropical and developing countries.

Authors:  Kanjaksha Ghosh; Vandana Pradhan; Kinjalka Ghosh
Journal:  Parasitol Res       Date:  2008-02-24       Impact factor: 2.289

4.  Autoantibody profile and other immunological parameters in recurrent spontaneous abortion patients.

Authors:  U Shankarkumar; V D Pradhan; M M Patwardhan; A Shankarkumar; K Ghosh
Journal:  Niger Med J       Date:  2011-07

5.  Clinical significance of HEp-2 cell cytoplasmic patterns in anti-neutrophil cytoplasmic antibody associated vasculitis.

Authors:  Naidan Zhang; Chaixia Ji; Xiao Bao; Chengliang Yuan
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

6.  Clinicopathologic Characteristics and Outcomes of Lupus Nephritis With Antineutrophil Cytoplasmic Antibody: A Retrospective Study.

Authors:  Yuan Wang; Xin Huang; Juan Cai; Lijiao Xie; Weili Wang; Sha Tang; Shiwei Yin; Xuejing Gao; Jun Zhang; Jinghong Zhao; Yunjian Huang; Yafei Li; Ying Zhang; Jingbo Zhang
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.